Key Highlights

  • Shares fell 4.65% to USD 19.29 on relative Volume of 2.01.
  • Third-quarter net loss was USD 61.2 million versus USD 80.5 million.
  • FDA granted Priority Review to the application, with a May 1, 2027 target date.
  • Cash and investments of USD 768.4 million are expected to fund operations into 2030.

uniQure (NASDAQ:QURE) shares traded at USD 19.29 on November 20, 2026, down 4.65%, with a relative volume at time of 2.01. The company has given no reason for the decline or the heavy trading. It announced FDA acceptance of its Biologics License Application on November 2 and filed its Quarterly Report on November 4, so both items predate the session.

uniQure N.V. is a Netherlands company based in Amsterdam, incorporated in 2012. It develops gene therapies for rare and other devastating diseases, with candidates for Huntington's disease, refractory mesial temporal lobe epilepsy and Fabry disease. It reports one segment, and its fiscal year ends December 31.

The Third Quarter

Revenues were USD 5.2 million versus USD 3.7 million. Research and Development expense was USD 35.5 million versus USD 34.4 million, and selling, general and administrative expense was USD 23.9 million versus USD 19.4 million. Operating expenses were USD 59.7 million versus USD 54.2 million, and the operating loss was USD 53.0 million versus USD 51.0 million.

Interest income was USD 8.1 million versus USD 3.5 million, and interest expense was USD 14.6 million versus USD 16.7 million. The net loss was USD 61.2 million versus USD 80.5 million, or USD 0.88 per share versus USD 1.38.

Nine Months and Balance Sheet

Nine-month revenues were USD 14.6 million versus USD 10.5 million. Research and development expense was USD 98.7 million versus USD 105.9 million, and selling, general and administrative expense was USD 61.4 million versus USD 43.8 million. The operating loss was USD 150.9 million versus USD 134.2 million, and the net loss was USD 195.8 million versus USD 161.9 million, or USD 2.95 per share versus USD 2.90.

Operating activities used USD 114.6 million versus USD 100.4 million. Cash was USD 98.4 million versus USD 80.2 million at December 31, 2025, and current Investment securities were USD 570.0 million versus USD 542.3 million. Equity was USD 294.7 million versus USD 198.9 million.

Huntington's Disease Application

In September, uniQure submitted a Biologics License Application to the FDA seeking Accelerated Approval of ifezuntirgene inilparvovec, also known as AMT-130, and a Marketing authorization application to the U.K. regulator, the MHRA, which validated it in the third quarter.

On November 2, the company said the FDA had accepted the application under the Accelerated Approval pathway and granted Priority Review with a PDUFA target action date of May 1, 2027. It said the FDA is tentatively planning to discuss the application at an Advisory Committee meeting, with the date and timelines still to be finalized.

The company said it and the FDA had aligned on key elements of a confirmatory study. The randomized trial would enroll about 200 patients in a 2:1 ratio of the therapy to standard of care, with Total Function Capacity at 36 months as the primary endpoint. Patient screening in the United States is planned to start by the end of 2026.

Outlook

On the November 4 call, management said cash, cash equivalents and investment securities should fund projected operating expenses into 2030, including commercial launch costs and the confirmatory study.

What to Watch Next for uniQure

The company has given no reason for the November 20 trading, and its results and regulatory news came earlier. The reported record shows a narrower quarterly net loss and a larger cash balance. The Advisory Committee date and the May 1, 2027 target action date are the points to follow.